

Certificate of Analysis

Cell count	1.9 million per vial
Viability	95%
CD4+	99.7%
CD4+CD25+	95.3%
CD25+CD127-	92.2%
% Suppression at 1:8 Treg:Effector Ratio	72 %
Sterility Testing	<i>Negative for bacteria, and fungi</i>

Donor Information





Donor ID	400
Sex	Male
Age	67
Race	Caucasian
Height	6'0"
Weight	245 lbs
ABO Type	A positive

HLA typing


	Allele 1	Allele 2
HLA-A	0201	6801
HLA-B	3901	4001
HLA-C	0319	0702
HLA-DRB1	0403	0801

Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Co-Culture of Tregs Resulted in Suppression of Anti- CD3-mediated CD8+ T Cell Proliferation of Allogeneic Peripheral Blood Mononuclear Cells (PBMCs). In short, in a 96 well plate, 250,000 CFSE-labelled allogeneic responder PBMC were plated/well in the presence of 0.2 µg/mL anti-CD3 and varying number of Tregs as shown in the chart above. The plate was incubated in a 37 deg C, 6% CO2 incubator. After 5 days of culture, individual wells were harvested and labelled with FITC-labelled anti-CD8 mAb. Data was acquired on a flow cytometer and the extent of proliferation (Division Index, DI) was analyzed using FCS Express 4.0. % Suppression = 100- (DI in the presence of Treg/DI in the absence of Treg) x 100.